CO2021008898A2 - Compuesto farmacéutico, método de fabricación y uso como agente medicinal - Google Patents
Compuesto farmacéutico, método de fabricación y uso como agente medicinalInfo
- Publication number
- CO2021008898A2 CO2021008898A2 CONC2021/0008898A CO2021008898A CO2021008898A2 CO 2021008898 A2 CO2021008898 A2 CO 2021008898A2 CO 2021008898 A CO2021008898 A CO 2021008898A CO 2021008898 A2 CO2021008898 A2 CO 2021008898A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystalline form
- manufacture
- pharmaceutical compound
- medicinal agent
- relates
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
RESUMEN La invención se refiere a una forma cristalina del Compuesto (I), en la que la forma cristalina muestra su reflexión más fuerte, indicada como un valor 2Θ, a 25±0.2°, en un patrón de difracción de polvo de rayos X. La invención también se refiere a un método de fabricación de esta forma cristalina, así como a composiciones farmacéuticas que la comprenden. Además, la invención se refiere a los métodos de uso de esta forma cristalina como medicamento y en el tratamiento del dolor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201812659A UA119735C2 (uk) | 2018-12-20 | 2018-12-20 | Фармацевтична сполука, спосіб її отримання та застосування як лікарського засобу |
| PCT/UA2019/000020 WO2020131000A1 (en) | 2018-12-20 | 2019-01-30 | Pharmaceutical compound, the method of its making and use as medicinal agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021008898A2 true CO2021008898A2 (es) | 2021-07-30 |
Family
ID=71102262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0008898A CO2021008898A2 (es) | 2018-12-20 | 2021-07-06 | Compuesto farmacéutico, método de fabricación y uso como agente medicinal |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3898596B1 (es) |
| JP (1) | JP7322151B2 (es) |
| KR (1) | KR102709767B1 (es) |
| CN (1) | CN113227059B (es) |
| BR (1) | BR112021012071A2 (es) |
| CO (1) | CO2021008898A2 (es) |
| EA (1) | EA202090281A1 (es) |
| ES (1) | ES2961011T3 (es) |
| HR (1) | HRP20231538T1 (es) |
| HU (1) | HUE064344T2 (es) |
| IL (1) | IL284132A (es) |
| MX (1) | MX2021007150A (es) |
| PL (1) | PL3898596T3 (es) |
| RS (1) | RS64880B1 (es) |
| UA (1) | UA119735C2 (es) |
| WO (1) | WO2020131000A1 (es) |
| ZA (1) | ZA202104617B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA115205C2 (uk) * | 2016-10-03 | 2017-09-25 | Товариство З Додатковою Відповідальністю "Інтерхім" | Застосування 7-бром-5-(о-хлорфеніл)-3-пропокси-1,2-дигідро-3н-1,4-бенздіазепін-2-ону для гальмування нейропатичного болю та судом різної етіології |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE621819A (es) * | 1961-08-29 | |||
| EP1548011A1 (en) * | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| JP2008174495A (ja) * | 2007-01-19 | 2008-07-31 | Reverse Proteomics Research Institute Co Ltd | 創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法 |
| UA108246C2 (xx) | 2011-05-10 | 2015-04-10 | Застосування 3-алкокси-1,2-дигідро-3н-1,4-бенздіазепін-2-онів як високоактивних анальгетичних агентів | |
| UA115205C2 (uk) | 2016-10-03 | 2017-09-25 | Товариство З Додатковою Відповідальністю "Інтерхім" | Застосування 7-бром-5-(о-хлорфеніл)-3-пропокси-1,2-дигідро-3н-1,4-бенздіазепін-2-ону для гальмування нейропатичного болю та судом різної етіології |
| CN107400115A (zh) * | 2017-08-04 | 2017-11-28 | 正大天晴药业集团股份有限公司 | 一种来那度胺的新结晶及其药物组合物 |
-
2018
- 2018-12-20 UA UAA201812659A patent/UA119735C2/uk unknown
-
2019
- 2019-01-30 EP EP19901248.5A patent/EP3898596B1/en active Active
- 2019-01-30 CN CN201980085152.7A patent/CN113227059B/zh active Active
- 2019-01-30 ES ES19901248T patent/ES2961011T3/es active Active
- 2019-01-30 HR HRP20231538TT patent/HRP20231538T1/hr unknown
- 2019-01-30 HU HUE19901248A patent/HUE064344T2/hu unknown
- 2019-01-30 KR KR1020217023027A patent/KR102709767B1/ko active IP Right Grant
- 2019-01-30 EA EA202090281A patent/EA202090281A1/ru unknown
- 2019-01-30 RS RS20231130A patent/RS64880B1/sr unknown
- 2019-01-30 BR BR112021012071-8A patent/BR112021012071A2/pt unknown
- 2019-01-30 WO PCT/UA2019/000020 patent/WO2020131000A1/en active Application Filing
- 2019-01-30 PL PL19901248.5T patent/PL3898596T3/pl unknown
- 2019-01-30 MX MX2021007150A patent/MX2021007150A/es unknown
- 2019-01-30 JP JP2021536107A patent/JP7322151B2/ja active Active
-
2021
- 2021-06-17 IL IL284132A patent/IL284132A/en unknown
- 2021-07-02 ZA ZA2021/04617A patent/ZA202104617B/en unknown
- 2021-07-06 CO CONC2021/0008898A patent/CO2021008898A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3898596C0 (en) | 2023-09-06 |
| EA202090281A1 (ru) | 2020-08-28 |
| RS64880B1 (sr) | 2023-12-29 |
| IL284132A (en) | 2021-08-31 |
| JP2022525579A (ja) | 2022-05-18 |
| KR20210106538A (ko) | 2021-08-30 |
| ZA202104617B (en) | 2023-12-20 |
| UA119735C2 (uk) | 2019-07-25 |
| JP7322151B2 (ja) | 2023-08-07 |
| WO2020131000A1 (en) | 2020-06-25 |
| US20220073474A1 (en) | 2022-03-10 |
| PL3898596T3 (pl) | 2024-02-26 |
| KR102709767B1 (ko) | 2024-09-24 |
| ES2961011T3 (es) | 2024-03-07 |
| EP3898596A1 (en) | 2021-10-27 |
| HUE064344T2 (hu) | 2024-03-28 |
| MX2021007150A (es) | 2021-08-19 |
| BR112021012071A2 (pt) | 2021-09-21 |
| CN113227059B (zh) | 2024-08-30 |
| CN113227059A (zh) | 2021-08-06 |
| HRP20231538T1 (hr) | 2024-03-15 |
| EP3898596A4 (en) | 2022-09-28 |
| EP3898596B1 (en) | 2023-09-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019004137A2 (es) | 1,2,4–triazolonas 2,4,5–trisustituidas | |
| ECSP17007538A (es) | 2-(morfolin-4-il)-1,7-naftiridinas | |
| UY37460A (es) | 1,2,4-triazolonas con anelación en 4 y 5 | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| CO2018004776A2 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana | |
| WO2015160842A8 (en) | Methods and formulations of capsaicinoids and capsinoids | |
| TN2017000467A1 (en) | Amido-substituted cyclohexane derivatives | |
| CU20200008A7 (es) | Compuestos de dihidrooxadiazinonas sustituidas útiles en el tratamiento de enfermedades hiperproliferativas, métodos para preparar dichos compuestos y composiciones farmacéuticas que los contienen | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| NI201700078A (es) | Pirazolpiridinaminas | |
| UY37577A (es) | Dihidroimidazopiridindionas sustituidas | |
| PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
| CO2019011877A2 (es) | Nuevos derivados de pirazol bicíclicos | |
| CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
| PE20151759A1 (es) | Imidazopiridazinas sustituidas | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| CL2018000430A1 (es) | Compuesto de hidroxitriazina y uso médico relacionado. | |
| CO2021008898A2 (es) | Compuesto farmacéutico, método de fabricación y uso como agente medicinal | |
| CL2019001004A1 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos. | |
| EP3668519A4 (en) | USE OF GINSENOSIDE M1 IN THE MANUFACTURE OF A MEDICINE FOR TREATMENT OF ORAL CANCER | |
| MX2021006464A (es) | Forma polimorfica de meisoindigo y formulacion modificada de meisoindigo. | |
| UY36983A (es) | Pirazolopiridinaminas sustituidas | |
| IT201700035757A1 (it) | Composizioni contenenti principi attivi naturali, loro preparazione ed uso nel trattamento della stipsi | |
| AR100820A1 (es) | Formulaciones de comprimido bi-capa de ciclofosfamida y capecitabina y administración metronómica altamente fraccionada de las mismas | |
| AR106645A1 (es) | Composiciones terapéuticas para el tratamiento del virus de inmunodeficiencia humana |